Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 2012